Sivik Global Healthcare LLC Has $7.20 Million Stake in Stryker Co. (NYSE:SYK)

Sivik Global Healthcare LLC lessened its position in Stryker Co. (NYSE:SYK) by 25.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the medical technology company’s stock after selling 7,000 shares during the quarter. Stryker comprises about 3.8% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 5th biggest position. Sivik Global Healthcare LLC’s holdings in Stryker were worth $7,201,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC grew its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the last quarter. Centennial Bank AR boosted its holdings in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $36,000. Crews Bank & Trust acquired a new stake in Stryker in the 4th quarter valued at $39,000. Finally, HBW Advisory Services LLC bought a new position in Stryker during the 3rd quarter valued at about $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 0.7 %

Shares of Stryker stock opened at $393.74 on Thursday. The business has a fifty day simple moving average of $376.44 and a two-hundred day simple moving average of $361.98. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The company has a market capitalization of $150.10 billion, a price-to-earnings ratio of 42.15, a P/E/G ratio of 2.68 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter in the prior year, the firm earned $3.46 earnings per share. Research analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.85%. Stryker’s dividend payout ratio is currently 36.01%.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Citigroup lifted their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday. Barclays raised their price target on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, Evercore ISI lifted their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $413.45.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.